ArrowMark Colorado Holdings’s Puma Biotechnology PBYI Stock Holding History

ArrowMark Colorado Holdings’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-21,000	Closed	-$2.19M	–	352
2014 Q1	$2.19M	Hold	21,000	–	–	0.07%	175
2013 Q4	$2.17M	Buy	21,000 +8,277	+65%	+$486K	0.07%	175
2013 Q3	$683K	Hold	12,723	–	–	0.02%	221
2013 Q2	$565K	Buy	+12,723	New	+$449K	0.15%	83

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ArrowMark Colorado Holdings's PBYI Position: Q2 2014 in Review

ArrowMark Colorado Holdings sold out of Puma Biotechnology (PBYI) in Q2 2014, closing a stake of 21,000 shares — an estimated $2.19M sold.

ArrowMark Colorado Holdings first reported a position in PBYI in Q2 2013 and held it in 4 quarters. The position peaked at $2.19M in Q1 2014. 138 funds tracked by Wall St. Rank hold PBYI as of Q2 2014.

ArrowMark Colorado Holdings reported no remaining Puma Biotechnology position as of Q2 2014 after selling out during the quarter.
ArrowMark Colorado Holdings sold 21,000 Puma Biotechnology shares in Q2 2014, an estimated $2.19M.
ArrowMark Colorado Holdings first reported a position in Puma Biotechnology in Q2 2013 and held it in 4 quarters.
ArrowMark Colorado Holdings's Puma Biotechnology position peaked at $2.19M in Q1 2014.
138 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2014.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2014, filed 14 Aug 2014.